Between 1995 and 2014, a majority of new drugs and medicines approved by the US Food and Drug Administration (FDA) recouped the average cost of drug development through net discounted sales within a ...
FDA commissioner Scott Gottlieb on Monday explained to attendees of RAPS’ Regulatory Convergence conference some steps FDA is taking to make the clinical end of drug development more efficient and ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
US drug pricing policy and Congressional Budget Office (CBO) model of the Build Back Better Act examining pharmaceutical R&D ...
Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...
Competition to create new brand-name drugs is a key driver of innovation in the United States. Unfortunately, it also drives the relentless growth of healthcare spending. That’s because development of ...
GLP-1 drugs – used to treat obesity and diabetes – now account for 38 per cent of projected sales and have displaced oncology ...
As President Donald Trump rolls out his TrumpRx proposal to cut prescription drug prices, economists are raising questions about what happens when prices are capped and whether short-term savings for ...
The Food and Drug Administration is relaxing regulations on biosimilar drugs used for cancer and rare diseases in the hopes of boosting competition and lowering prices for high-cost pharmaceuticals.
In Detroit, they say that we don’t have healthcare in our country, we have sick care. Under the Trump Administration, our ...
Researchers at Kent have established a computational protocol that could accelerate the development of more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results